PROVIDE-HF STUDY RESULTS: PATIENT-REPORTED OUTCOMES INVESTIGATION FOLLOWING INITIATION OF DRUG THERAPY WITH ENTRESTO (SACUBITRIL/VALSARTAN) IN HEART FAILURE

Robert J. Mentz,Haolin Xu,Emily C. O’Brien,Laine Thomas,Tamas Alexy,Bhanu Gupta,Juan Vilaro,Anuradha (Anu) Lala,Ravi Dhingra,Alexandros Briasoulis,Marc A. Simon,Josef Stehlik,Jo E. Rodgers,Shannon M. Dunlay,Martha Abshire,Quinn Wells,Kurt G. Barringhaus,Peter Eckman,Brian Lowes,Johana Espinoza,Rosalia Blanco,Xian Shen,Carol I. Duffy,Adrian F. Hernandez

PROVIDE-HF STUDY RESULTS: PATIENT-REPORTED OUTCOMES INVESTIGATION FOLLOWING INITIATION OF DRUG THERAPY WITH ENTRESTO (SACUBITRIL/VALSARTAN) IN HEART FAILURE

2020

PARADIGM-HF showed that sacubitril/valsartan (sac/val) improved quality of life (QOL) vs enalapril in heart failure with reduced ejection fraction (HFrEF), yet limited data are available regarding QOL changes after sac/val initiation in routine practice. PROVIDE-HF was a prospective study of HFrEF

Keywords:

Diabetes mellitus
Sacubitril, Valsartan
Medicine
Cardiology
Pharmacotherapy
Internal medicine
Heart failure
Ejection fraction
Prospective cohort study
Sacubitril
Enalapril
Quality of life
Valsartan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations